Development of DNA vaccine for Angiotensin II

点击翻译按钮获取中文摘要

Vaccines have been recently developed to treat various diseases such as cancer, rheumatoid arthritis and Alzheimer’s disease. However, before use in the clinical setting, vaccines targeting self-antigens must be demonstrated to be effective and safe, evoking an adequate humoral immune response from B cells. In this study, we evaluated the efficiency and safety of an Ang II vaccine in mice and rats. Immunization with Ang II conjugated to KLH successfully induced the production of anti-Ang II antibody. In an Ang II-infused model, the non-immunized mice showed high blood pressure (BP), whereas the immunized mice (Ang II-KLH) showed a significant decrease in systolic BP. In terms of DNA vaccine, plasmid vector encoding hepatitis B core (HBc)- Ang II fusion protein was injected into spontaneously hypertensive rats (SHR). Anti-Ang II antibody was successfully produced in HBc-Ang II group, and antibody titers were sustained for at least 6 months. Systolic BP was consistently lower in HBc-Ang II group after immunization.